The relevance of the reference range for EGFR testing in non-small cell lung cancer patients

IF 4.5 2区 医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2024-10-28 DOI:10.1016/j.lungcan.2024.108002
{"title":"The relevance of the reference range for EGFR testing in non-small cell lung cancer patients","authors":"","doi":"10.1016/j.lungcan.2024.108002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Identifying mutations in the epidermal growth factor receptor (<em>EGFR</em>) gene is crucial for individualized treatment of non-small cell lung cancer (NSCLC) patients. Accordingly, several methodologies and instruments are now commercially available to detect these alterations. The aim of this study was to examine the performance of next generation sequencing (NGS) in detecting both common and uncommon <em>EGFR</em> gene mutations in advanced NSCLC patients.</div></div><div><h3>Methods</h3><div>We retrospectively retrieved molecular data from n = 1312 advanced stage NSCLC patients tested by our NGS DNA-based panel (namely SiRe® panel) from January 2018 to December 2022. We subsequently compared the NGS results with the reference ranges of the most popular real time PCR (RT-qPCR) assays (cobas® <em>EGFR</em> Mutation Test v2, EasyPGX® ready <em>EGFR</em>, Idylla™ <em>EGFR</em> mutation test, and therascreen® <em>EGFR</em> Plus RGQ).</div></div><div><h3>Results</h3><div>Overall, NGS detected n = 234 mutations in n = 192 (15.9 %) patients. Conversely, when these results were compared with the reference ranges of the four most common commercially available RT-qPCR assays, far fewer mutations were identified: n = 18 (9.4 %), n = 17 (8.9 %), n = 17 (8.9 %), and n = 18 (9.4 %) mutations. These results suggest that if patients were tested solely using RT-qPCR assays, a substantial proportion would have been ineligible for targeted therapies.</div></div><div><h3>Conclusions</h3><div>Our study highlights that NGS is able to identify a much higher number of actionable <em>EGFR</em> mutations than RT-qPCR approaches, thereby providing many more patients the opportunity to receive targeted EGFR treatments.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0169500224005361","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Identifying mutations in the epidermal growth factor receptor (EGFR) gene is crucial for individualized treatment of non-small cell lung cancer (NSCLC) patients. Accordingly, several methodologies and instruments are now commercially available to detect these alterations. The aim of this study was to examine the performance of next generation sequencing (NGS) in detecting both common and uncommon EGFR gene mutations in advanced NSCLC patients.

Methods

We retrospectively retrieved molecular data from n = 1312 advanced stage NSCLC patients tested by our NGS DNA-based panel (namely SiRe® panel) from January 2018 to December 2022. We subsequently compared the NGS results with the reference ranges of the most popular real time PCR (RT-qPCR) assays (cobas® EGFR Mutation Test v2, EasyPGX® ready EGFR, Idylla™ EGFR mutation test, and therascreen® EGFR Plus RGQ).

Results

Overall, NGS detected n = 234 mutations in n = 192 (15.9 %) patients. Conversely, when these results were compared with the reference ranges of the four most common commercially available RT-qPCR assays, far fewer mutations were identified: n = 18 (9.4 %), n = 17 (8.9 %), n = 17 (8.9 %), and n = 18 (9.4 %) mutations. These results suggest that if patients were tested solely using RT-qPCR assays, a substantial proportion would have been ineligible for targeted therapies.

Conclusions

Our study highlights that NGS is able to identify a much higher number of actionable EGFR mutations than RT-qPCR approaches, thereby providing many more patients the opportunity to receive targeted EGFR treatments.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非小细胞肺癌患者表皮生长因子受体检测参考范围的相关性
导言确定表皮生长因子受体(EGFR)基因的突变对于非小细胞肺癌(NSCLC)患者的个体化治疗至关重要。因此,目前市场上有多种方法和仪器可用于检测这些基因突变。本研究旨在检测新一代测序(NGS)在检测晚期 NSCLC 患者常见和不常见表皮生长因子受体基因突变方面的性能。方法我们回顾性地检索了 2018 年 1 月至 2022 年 12 月期间通过我们基于 NGS DNA 的面板(即 SiRe® 面板)检测的 n = 1312 例晚期 NSCLC 患者的分子数据。随后,我们将 NGS 结果与最流行的实时 PCR (RT-qPCR) 检测方法(cobas® EGFR 突变检测 v2、EasyPGX® ready EGFR、Idylla™ EGFR 突变检测和 therascreen® EGFR Plus RGQ)的参考范围进行了比较。结果总体而言,NGS 在 n = 192(15.9%)名患者中检测到 n = 234 个突变。相反,当这些结果与四种最常见的市售 RT-qPCR 检测方法的参考范围进行比较时,发现的突变少得多:n = 18(9.4%)、n = 17(8.9%)、n = 17(8.9%)和 n = 18(9.4%)个突变。这些结果表明,如果仅使用 RT-qPCR 检测方法对患者进行检测,很大一部分患者将不符合接受靶向治疗的条件。结论我们的研究强调,与 RT-qPCR 方法相比,NGS 能够鉴定出更多可操作的表皮生长因子受体突变,从而为更多患者提供接受表皮生长因子受体靶向治疗的机会。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Lung Cancer
Lung Cancer 医学-呼吸系统
CiteScore
9.40
自引率
3.80%
发文量
407
审稿时长
25 days
期刊介绍: Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.
期刊最新文献
Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS Corrigendum to "Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK -positive advanced non-small cell lung cancer" [Lung Cancer 195 (2024) 107919]. Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer The relevance of the reference range for EGFR testing in non-small cell lung cancer patients Treatment with trimetazidine dihydrochloride and lung cancer survival: Implications on metabolic re-programming
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1